Skip to content

Medical emergency? What to do

U.S. panel backs use of Bayer heart surgery drug

3-RXPublished September 26, 20063 min read

Key points

  • Bayer AG's drug Trasylol provides acceptable safety and effectiveness for preventing blood loss in certain patients undergoing heart bypass surgery, a U.S. advisory panel said on Thursday.
  • The experts from outside the FDA agreed Trasylol treatment appeared linked to a higher rate of kidney dysfunction but many questioned the validity of research that found a connection to heart attacks and strokes.
  • In February, the FDA urged doctors to limit Trasylol use while the agency evaluated two studies linking the drug to kidney problems.
  • Agency officials asked the panel for input as they decide if new warnings or other steps are needed.

Bayer AG's drug Trasylol provides acceptable safety and effectiveness for preventing blood loss in certain patients undergoing heart bypass surgery, a U.S. advisory panel said on Thursday.

The Food and Drug Administration advisers voted in favor of Trasylol after reviewing data on heart attacks, strokes, kidney damage and allergic reactions in people treated with the drug.

The experts from outside the FDA agreed Trasylol treatment appeared linked to a higher rate of kidney dysfunction but many questioned the validity of research that found a connection to heart attacks and strokes.

"I think the totality of evidence does support its use," said Dr. William Hiatt, the panel chairman and a vascular medicine specialist at the University of Colorado Health Sciences Center.

In February, the FDA urged doctors to limit Trasylol use while the agency evaluated two studies linking the drug to kidney problems. One of the studies said Trasylol could increase the chances of heart attacks and strokes as well.

FDA reviewers said they also became concerned by the number of fatal allergic reactions reported. A total of 51 have been recorded, including 10 in 2005.

Agency officials asked the panel for input as they decide if new warnings or other steps are needed.

Trasylol, known generically as aprotinin, is given by injection to prevent blood loss during cardiac bypass surgery. It won U.S. clearance in 1993 and is the only FDA-approved medicine for that use, although doctors often turn to two older, generic drugs for the same purpose, experts said.

Between 10 percent and 20 percent of all blood transfusions in the United States occur during heart surgery, which strains the blood supply and poses some risks to patients, Bayer said.

Eighteen panel members supported continued use of Trasylol in heart bypass patients, and one abstained from voting. Several said Trasylol should be reserved for patients considered at high risk of bleeding.

"I think there still needs to be caution in not using it routinely in everyone," said panel member Dr. Norman Kato, a cardiovascular surgeon at Cardiac Care Medical Group in Encino, California.

Bayer said it had proposed adding information about kidney risks to the drug label but believed the drug's benefits still outweighed the risks.

The German company also said it was developing a test it hoped could identify patients at risk for an allergic reaction. Trasylol already carries a strong "black box" warning that a fatal allergic reaction could occur, and doctors are urged to give a small test dose first.

The company and several panelists criticized a study, published in the New England Journal of Medicine in January that concluded Trasylol raised the chances of suffering a heart attack or stroke. They said the researchers might not have accounted for other factors that could be to blame.

"I think this drug is fairly neutral" on problems such as heart attacks and strokes, Hiatt said.

The lead author of that study, Dr. Dennis Mangano, defended his results to the panel and said continued use of Trasylol was "not prudent."

Trasylol sales were 75 million euros ($95 million) for the first half of 2006. In December 2005, Bayer predicted the drug's annual sales could reach more than 500 million euros ($635 million).

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underHeart

Keep reading

Heart

Early sexual abuse increases heart risks

Women who were repeatedly sexually abused as girls have a 62 percent higher risk of heart problems later in life compared with women who were not abused, U.S. researchers said on Sunday. The findings, presented at…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.